These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36209235)

  • 61. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Best approaches to drug-resistance surveillance at the country level.
    Cabibbe AM; Cirillo DM
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S40-S41. PubMed ID: 28043601
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Whole-genome sequencing analysis of multidrug-resistant
    Tania T; Sudarmono P; Kusumawati RL; Rukmana A; Pratama WA; Regmi SM; Kaewprasert O; Chaiprasert A; Chongsuvivatwong V; Faksri K
    J Med Microbiol; 2020 Jul; 69(7):1013-1019. PubMed ID: 32579102
    [No Abstract]   [Full Text] [Related]  

  • 65. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Homeopathic treatment in addition to standard care in multi drug resistant pulmonary tuberculosis: a randomized, double blind, placebo controlled clinical trial.
    Chand KS; Manchanda RK; Mittal R; Batra S; Banavaliker JN; De I
    Homeopathy; 2014 Apr; 103(2):97-107. PubMed ID: 24685414
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 68. TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol.
    Rachow A; Ivanova O; Wallis R; Charalambous S; Jani I; Bhatt N; Kampmann B; Sutherland J; Ntinginya NE; Evans D; Lönnroth K; Niemann S; Schaible UE; Geldmacher C; Sanne I; Hoelscher M; Churchyard G
    BMC Pulm Med; 2019 Jan; 19(1):4. PubMed ID: 30616617
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Drug resistance patterns among extra-pulmonary tuberculosis cases in a tertiary care centre in North India.
    Sharma SK; Chaubey J; Singh BK; Sharma R; Mittal A; Sharma A
    Int J Tuberc Lung Dis; 2017 Oct; 21(10):1112-1117. PubMed ID: 28911354
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The impact of a knowledge translation intervention employing educational outreach and a point-of-care reminder tool vs standard lay health worker training on tuberculosis treatment completion rates: study protocol for a cluster randomized controlled trial.
    Puchalski Ritchie LM; van Lettow M; Makwakwa A; Chan AK; Hamid JS; Kawonga H; Martiniuk AL; Schull MJ; van Schoor V; Zwarenstein M; Barnsley J; Straus SE
    Trials; 2016 Sep; 17(1):439. PubMed ID: 27604571
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Accuracy of whole genome sequencing versus phenotypic (MGIT) and commercial molecular tests for detection of drug-resistant Mycobacterium tuberculosis isolated from patients in Brazil and Mozambique.
    Feliciano CS; Namburete EI; Rodrigues Plaça J; Peronni K; Dippenaar A; Warren RM; Silva WA; Bollela VR
    Tuberculosis (Edinb); 2018 May; 110():59-67. PubMed ID: 29779775
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Management of Multidrug-Resistant Tuberculosis.
    Daley CL; Caminero JA
    Semin Respir Crit Care Med; 2018 Jun; 39(3):310-324. PubMed ID: 30071546
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Addressing challenges in tuberculosis adherence via performance-based payments for integrated case management: protocol for a cluster randomized controlled trial in Georgia.
    Chikovani I; Diaconu K; Duric P; Sulaberidze L; Uchaneishvili M; Mohammed NI; Zoidze A; Witter S
    Trials; 2019 Aug; 20(1):536. PubMed ID: 31462284
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study.
    Pankhurst LJ; Del Ojo Elias C; Votintseva AA; Walker TM; Cole K; Davies J; Fermont JM; Gascoyne-Binzi DM; Kohl TA; Kong C; Lemaitre N; Niemann S; Paul J; Rogers TR; Roycroft E; Smith EG; Supply P; Tang P; Wilcox MH; Wordsworth S; Wyllie D; Xu L; Crook DW;
    Lancet Respir Med; 2016 Jan; 4(1):49-58. PubMed ID: 26669893
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
    Katende B; Esterhuizen TM; Dippenaar A; Warren RM
    Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.